Abstract | CONTEXT: EVIDENCE ACQUISITION: A review of published, peer-reviewed medical literature (1990 to June 2009) on the physiology and pathophysiology of 11beta-HSD1 was performed with an emphasis on HPA axis consequences, the metabolic syndrome, and the inflammatory response. EVIDENCE SYNTHESIS: Studies of patients with genetic defects in 11beta-HSD1 action show abnormal HPA axis responses with hyperandrogenism being a major consequence. The mechanisms underlying these abnormalities have been explored in mouse models with targeted deletion of components of the 11beta-HSD1 system. A range of experimental studies emphasize the role of 11beta-HSD1 in the metabolic syndrome and the potential for treatment with chemical inhibitors. An emerging area is the role of 11beta-HSD1 in the inflammatory response. CONCLUSIONS:
11Beta-HSD1 activity is an important component of the HPA axis and contributes to the metabolic syndrome and the normal immune response. Ongoing clinical observations and the development of selective inhibitors will further clarify the role of 11beta-HSD1 in these areas.
|
Authors | Mark S Cooper, Paul M Stewart |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 94
Issue 12
Pg. 4645-54
(Dec 2009)
ISSN: 1945-7197 [Electronic] United States |
PMID | 19837912
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- 11-beta-Hydroxysteroid Dehydrogenase Type 1
|
Topics |
- 11-beta-Hydroxysteroid Dehydrogenase Type 1
(genetics, physiology)
- Adipose Tissue
(metabolism)
- Animals
- Humans
- Hypothalamo-Hypophyseal System
(physiology)
- Inflammation
(enzymology, genetics)
- Metabolic Syndrome
(enzymology, genetics)
- Mice
- Pituitary-Adrenal System
(physiology)
|